Heart Failure Clinical Trials
For more information on Heart Failure trials or to refer a patient, please contact Gail Snell, RN, at gsnell@emory.edu or 404-712-0531.
Atomic-AHF | Avoid-HF | Exact-HF | Improve-HF | Rose-AHF | Tactics-AHF
ATOMIC-AHF
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure
Purpose: To evaluate the effect of 48 hours of intravenous omecamtiv mecarbil on dyspnea in patients with left ventricular systolic dysfunction hospitalized for acute heart failure.
Inclusion Criteria:
- Age 18 - 85 years
- Hospitalized for worsening heart failure, within 24 hours of initiating loop diuretics
- Dyspnea due to heart failure, at rest or with minimal exertion
- History of left ventricular ejection fraction ≤ 40%
- Elevated brain natriuretic peptide (BNP) or N-terminal fragment BNP
Purpose: To determine if patients hospitalized for heart failure have fewer repeat hospital admissions and emergency room visits for heart failure (up to 90 days of discharge) after receiving aquapheresis therapy compared to intravenous diuretics.
Inclusion Criteria:
- 18 years of age
- Admitted to the hospital with a primary diagnosis of acute decompensated heart failure
- Must be able to be enrolled into the trial ≤ 24 hours of admission to the hospital
- On oral loop diuretics prior to admission
- Fluid overload (two of: edema, jugular venous distention, pulmonary edema, paroxysmal nocturnal dyspnea, ≥2 pillow orthopnea, or respiration rate ≥ 20 per minute)
- Have received ≤ 2 intravenous loop diuretics doses
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Purpose: To determine whether allopurinol is effective in relieving symptoms of patients with heart failure and high blood uric acid levels.
Inclusion Criteria:
- ≥18 years of age
- Heart failure due to ischemic or non-ischemic cardiomyopathy
- Left ventricular ejection fraction ≤ 40% by echocardiography
- Heart failure symptoms for 3 months despite therapy
- Serum uric acid level ≥9.5 mg/dl
- At least one of the following conditions: hospitalization, emergency room, or urgent clinic visit for heart failure requiring intravenous diuretics within the previous 12 months; left ventricular ejection fraction ≥25%; B-type natriuretic peptide level >250 pg/ml
IMPROVE-HF
Improve-HF Bridge Pilot Study
Purpose: To test a strategy of bridging (1) the transition of care from inpatient to outpatient with expert evaluation and (2) the communication gap between specialty and primary care.
Inclusion Criteria:
- ≥18 years of age
- Current hospitalization for worsening heart failure requiring intravenous loop diuretics
- History of chronic heart failure for at least 3 months
- Left ventricular ejection fraction < 35% within 3 months
ROSE-AHF
Renal Optimization Strategies Evaluation in Acute Heart Failure
Purpose: To determine the benefits and safety of intravenous administration of low dose nesiritide or low dose dopamine in patients with congestive heart failure and kidney dysfunction.
Inclusion Criteria:
- ≥18 years of age
- Hospital admission for heart failure (at least one symptom and one sign present)
- Prior diagnosis of heart failure with daily home use of oral loop diuretic for at least 1 month
- Must be identified within 24 hours of hospital admission
- Glomerular filtration rate ≥15 but ≤60 mL/min/1.73m2
TACTICS-HF
Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure
Purpose: To see if taking tolvaptan by mouth in addition to regular treatment received for shortness of breath due to heart failure will work better than regular treatment alone. The study will also look if other symptoms or problems associated with heart failure, like changes in kidney function, are affected by tolvaptan.
Inclusion Criteria:
- 18 years of age
- Daily oral dose of furosemide between 40 and 240mg (or equivalent)
- Admission for acute decompensated heart failure as determined by dyspnea at rest or with minimal exertion, B-type natriuretic peptide (BNP) >400 pg/ml or N-terminal fragment BNP >2000 pg/mL, and at least one sign or symptom of heart failure.
- Identified within 24 hours from initial dose of intravenous loop diuretic
- Prior clinical diagnosis of heart failure treated with oral loop diuretics for at least 1 month